Immunodeficiency 32AD81.4

Last updated on: 12.04.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

The very rare immunodeficiency 32A is caused by an autosomal dominant IRF8 deficiency.

This deficiency causes an abnormal myeloid phenotype in the peripheral blood with a marked loss of CD11C-positive dendritic cells.

The dysfunction results in selective susceptibility to mycobacterial infections, an immune deficiency termed Mendelian susceptibility to mycobacterial diseases -MSMD (Hambleton et al. 2011).

MSMD is a rare disease characterized by a predisposition to disease caused by low virulence mycobacteria (e.g., BCG vaccines and environmental mycobacteria) in otherwise healthy individuals. MSMD do not show abnormalities in routine hematological and immunological tests.

Note(s)This section has been translated automatically.

The designation MSMD does not reflect all clinical features, as patients are also susceptible to salmonellosis, candidiasis, and tuberculosis, and less commonly to infections with other intramacrophageous bacteria, fungi, or parasites, and perhaps even some viruses.

LiteratureThis section has been translated automatically.

Lit

  1. Bustamante J et al (2014) Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol 26:454-470.
  2. DiNardo CD et al.(2016) Mutations in AML: prognostic and therapeutic implications. Hematol. Am Soc Hematol Educ Program 2016:348-355.
  3. Hambleton S et al (2011) IRF8 mutations and human dendritic-cell immunodeficiency. New Eng. J Med 365: 127-138.
  4. Liss F et al (2021) IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells. Cancers (Basel) 13:764.
  5. Mace EM et al (2017) Biallelic mutations in IRF8 impair human NK cell maturation and function. J Clin Invest 127: 306-320.

Last updated on: 12.04.2022